Designing drug occupancy studies with PET neuroimaging: Sample size, occupancy ranges and analytical methods
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Designing drug occupancy studies with PET neuroimaging : Sample size, occupancy ranges and analytical methods. / Laurell, Gjertrud Louise; Plavén-Sigray, Pontus; Svarer, Claus; Ogden, R. Todd; Knudsen, Gitte Moos; Schain, Martin.
In: NeuroImage, Vol. 263, 119620, 2022.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Designing drug occupancy studies with PET neuroimaging
T2 - Sample size, occupancy ranges and analytical methods
AU - Laurell, Gjertrud Louise
AU - Plavén-Sigray, Pontus
AU - Svarer, Claus
AU - Ogden, R. Todd
AU - Knudsen, Gitte Moos
AU - Schain, Martin
N1 - Publisher Copyright: © 2022
PY - 2022
Y1 - 2022
N2 - Molecular neuroimaging is today considered essential for evaluation of novel CNS drugs; it is used to quantify blood-brain barrier permeability, verify interaction with key target and determine the drug dose resulting in 50% occupancy, IC50. In spite of this, there has been limited data available to inform on how to optimize study designs. Through simulations, we here evaluate how IC50 estimation is affected by the (i) range of drug doses administered, (ii) number of subjects included, and (iii) level of noise in the plasma drug concentration measurements. Receptor occupancy is determined from PET distribution volumes using two different methods: the Lassen plot and Likelihood estimation of occupancy (LEO). We also introduce and evaluate a new likelihood-based estimator for direct estimation of IC50 from PET distribution volumes. For estimation of IC50, we find very limited added benefit in scanning individuals who are given drug doses corresponding to less than 40% receptor occupancy. In the range of typical PET sample sizes (5–20 subjects) each extra individual clearly reduces the error of the IC50 estimate. In all simulations, likelihood-based methods gave more precise IC50 estimates than the Lassen plot; four times the number of subjects were required for the Lassen plot to reach the same IC50 precision as LEO.
AB - Molecular neuroimaging is today considered essential for evaluation of novel CNS drugs; it is used to quantify blood-brain barrier permeability, verify interaction with key target and determine the drug dose resulting in 50% occupancy, IC50. In spite of this, there has been limited data available to inform on how to optimize study designs. Through simulations, we here evaluate how IC50 estimation is affected by the (i) range of drug doses administered, (ii) number of subjects included, and (iii) level of noise in the plasma drug concentration measurements. Receptor occupancy is determined from PET distribution volumes using two different methods: the Lassen plot and Likelihood estimation of occupancy (LEO). We also introduce and evaluate a new likelihood-based estimator for direct estimation of IC50 from PET distribution volumes. For estimation of IC50, we find very limited added benefit in scanning individuals who are given drug doses corresponding to less than 40% receptor occupancy. In the range of typical PET sample sizes (5–20 subjects) each extra individual clearly reduces the error of the IC50 estimate. In all simulations, likelihood-based methods gave more precise IC50 estimates than the Lassen plot; four times the number of subjects were required for the Lassen plot to reach the same IC50 precision as LEO.
KW - IC
KW - Kinetic modeling
KW - Lassen plot
KW - PET study design
KW - Receptor occupancy
KW - [C]Cimbi-36
U2 - 10.1016/j.neuroimage.2022.119620
DO - 10.1016/j.neuroimage.2022.119620
M3 - Journal article
C2 - 36087903
AN - SCOPUS:85138028971
VL - 263
JO - NeuroImage
JF - NeuroImage
SN - 1053-8119
M1 - 119620
ER -
ID: 321645054